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A B S T R A C T
Background: Comorbid anxiety symptoms and disorders are present in many psychiatric disorders, but
methodological variations render comparisons of their frequency and intensity difficult. Furthermore,
whether risk factors for comorbid anxiety symptoms are similar in patients with mood disorders and
schizophrenia spectrum disorders remains unclear.
Methods: The Overall Anxiety Severity and Impairment Scale (OASIS) was used to measure anxiety
symptoms in psychiatric care patients with schizophrenia or schizoaffective disorder (SSA, n = 113),
bipolar disorder (BD, n = 99), or depressive disorder (DD, n = 188) in the Helsinki University Psychiatric
Consortium Study. Bivariate correlations and multivariate linear regression models were used to
examine associations of depressive symptoms, neuroticism, early psychological trauma and distress, self-
efficacy, symptoms of borderline personality disorder, and attachment style with anxiety symptoms in
the three diagnostic groups.
Results: Frequent or constant anxiety was reported by 40.2% of SSA, 51.5% of BD, and 55.6% of DD patients;
it was described as severe or extreme by 43.8%, 41.4%, and 41.2% of these patients, respectively. SSA
patients were significantly less anxious (P = 0.010) and less often avoided anxiety-provoking situations
(P = 0.009) than the other patients. In regression analyses, OASIS was associated with high neuroticism,
symptoms of depression and borderline personality disorder and low self-efficacy in all patients, and
with early trauma in patients with mood disorders.
Conclusions: Comorbid anxiety symptoms are ubiquitous among psychiatric patients with mood or
schizophrenia spectrum disorders, and in almost half of them, reportedly severe. Anxiety symptoms
appear to be strongly related to both concurrent depressive symptoms and personality characteristics,
regardless of principal diagnosis.
 2016 Elsevier Masson SAS. All rights reserved.
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Anxiety symptoms are conceptualized as anxiety disorders
(ADs) when they constitute specified syndromes and are intensive,
recurrent, and impede an individual’s psychosocial functioning* Corresponding author. Tel.: +358 9 4711; fax: +358 9 471 6373.
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0924-9338/ 2016 Elsevier Masson SAS. All rights reserved.[1]. ADs are the most common psychiatric conditions in the general
population, with typical estimates for lifetime prevalence of
16–28% [2–5]. ADs also commonly co-occur with other psychiatric
conditions. For instance, up to 38% of patients with schizophrenia
[6], 45% of patients with bipolar disorder [7], and 73% of patients
with depression [8] reportedly suffer from a lifetime comorbid
AD(s). ADs impair quality of life and are associated with poorer
prognosis and outcome of psychotic and affective disorders
[9–13]. This is true also for comorbid subthreshold anxiety
[14–16]. Thus, careful recognition and proper treatment of
comorbid anxiety, either as diagnosable disorders or as subthresh-
old states, are important in clinical practice.
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patients with major mental disorders exists [6,17,18]. The majority
of these studies have focused on the presence of specific comorbid
disorders [19], rarely reporting on subthreshold anxiety symp-
toms, even if clinically relevant. Few studies on comorbid anxiety
disorders or symptoms have included both uni- and bipolar mood
as well as non-affective psychotic disorders, and methodological
variations have rendered comparisons of the results difficult.
Hence, it remains unclear whether prevalence of anxiety
symptoms and their putative risk factors are similar in patients
with schizophrenia or schizoaffective disorder (SSA), bipolar
disorder (BD), and depressive disorder (DD).
Anxiety and depressive disorders constitute the main internal-
izing mental disorders [20,21], with a high level of temporal
covariation [22]. Recent studies have found that bipolar disorder
shares some etiological and pathogenetic connections with the
internalizing domain as well [23,24]. The internalizing disorders
are likely to share most of their genetic basis [25–27]. The
personality trait of high neuroticism is the most significant risk
factor for internalizing pathology [28,29] and a likely mediator of
the underlying genetic diathesis for these disorders [30]. However,
many other putative risk factors also contribute to the anxiety and
depressive disorders. These factors include childhood and adoles-
cence psychological trauma [31], low self-efficacy [32,33],
borderline personality disorder [34], and negative experiences in
close relationships [35]. Some findings indicate that the same
factors could also affect the onset of schizophrenia and worsen its
outcome [36–39]. However, whether similar covariation of
depressive and anxiety symptoms exists and whether the same
putative risk factors underlie anxiety in schizophrenia spectrum
disorders and internalizing disorders remain unclear.
This study had both clinical and theoretical aims. The clinical
aim was to compare the point prevalence of comorbid anxiety
symptoms among psychiatric patients with depression, bipolar
disorder, and schizophrenia or schizoaffective disorders. We
hypothesized that the level of anxiety symptoms in patients with
schizophrenia or schizoaffective disorder would be lower since, in
contrast to mood disorders, these psychotic disorders are not
diagnostically defined by the presence of negative affect as a
central pathognomonic feature. The theoretical aim was to
investigate the relationships of anxiety symptoms with neuroti-
cism, depressive symptoms, and other putative risk factors. We
expected that anxiety symptoms would show a clear association
with these factors in patients with mood disorders, and explored
whether the same relationships would apply to patients with




The current study was a part of the Helsinki University
Psychiatric Consortium (HUPC) study performed in collaboration
between the Faculty of Medicine, University of Helsinki; the
Department of Psychiatry, Helsinki University Central Hospital; the
Department of Health and the Mental Health Unit of the National
Institute of Health and Welfare, Helsinki; the Department of Social
Services and Health Care, Psychiatric Services, Helsinki; and the
Department of Psychiatry, Helsinki City Health Department. The
catchment area with 1,139,222 inhabitants in 2012 covered the
metropolitan area of Helsinki, including the municipalities of
Helsinki, Espoo, Vantaa, Kauniainen, Kerava, and Kirkkonummi.
Specialized secondary mental health service is provided to these
residents. The study was carried out in 10 community mental healthcenters, in 24 psychiatric inpatient units, in one day-care hospital,
and in two residential communities. The HUPC study was approved
by the Ethics Committee of Helsinki University Hospital and the
pertinent institutional authorities.
2.2. Sampling
Stratified patient sampling was performed from 12 January
2011 to 20 December 2012. Patients were randomly drawn either
by identifying all eligible patients on a certain day or week in a unit
or from patient lists. Inclusion criteria were age from 18 to 64 years
and provision of written informed consent. Patients with mental
retardation, neurodegenerative disorders, and insufficient Finnish
language skills were excluded. Of the 1361 eligible patients,
610 declined to participate and 304 were lost for other reasons. The
final number of participants was 447, yielding a response rate of
33%. For the current study, patients with a principal diagnosis of
anxiety disorder, eating disorder, neuropsychiatric disorder, or
substance use disorder (n = 47) were excluded from the final
analyses due to the low number of patients in each group. The total
number of patients, thus, was 400.
2.3. Diagnostic assessment
Diagnostic assessments were made according to the Interna-
tional Statistical Classification of Diseases and Related Health
Problems, 10th Revision [40] following the principle of lifetime
main diagnosis. The authors (K.A, I.B., M.K., and B.K.) verified the
clinical diagnoses given by attending psychiatrists by re-examin-
ing information obtained from all available medical records. In
cases of any diagnostic uncertainty, the senior research psychia-
trists (G.J. and E.I.) were consulted. Altogether, 69 cases were
consulted. According to the principal diagnosis, patients were
divided into three diagnostic groups: schizophrenia or schizoaf-
fective disorder (SSA, n = 113), bipolar disorder (BD, n = 99), and
depressive disorder (DD, n = 188).
2.4. Measurement of symptoms and traits
Overall Anxiety Severity and Impairment Scale (OASIS) [41] is a
brief, 5-item self-report questionnaire to assess severity and
impairment associated with any anxiety disorder, multiple anxiety
disorders, or subthreshold anxiety. The authors of the current
article translated the OASIS into Finnish, which was then back
translated into English and the translation revised in collaboration
with the creator of OASIS, Dr. Sonya Norman. The questionnaire
includes five questions regarding the frequency and severity of
anxiety symptoms as well as anxiety-related avoidance behavior
and decreased functioning at home/work/school and in social life.
Responses range from zero (no anxiety or anxiety-related issues) to
four (extreme anxiety and massive anxiety-related issues). A
recommended cut-off score for screening of anxiety disorder is
eight points [42]. Cronbach’s alpha for OASIS in the total sample
was 0.84, and specifically, 0.88 for SSA, 0.86 for BD, and 0.78 for DD
patients, showing good internal consistency overall and in the
subgroups.
Beck Depression Inventory (BDI) [43] is a 21-item self-report
questionnaire for measuring the severity of depression symptoms.
The ‘‘Short Five’’ (S5) [44] is a 60-item questionnaire constructed
for measuring 30 facets of the Five-Factor Model identified by the
NEO (Neuroticism-Extraversion-Openness) Personality Inventory.
The current study used six items describing neuroticism (S5N). The
S5N scale as well as the other four scales (Extraversion, Openness,
Agreeableness, and Conscientiousness) showed good internal
consistency (Cronbach’s alpha for S5N see below, other values
not shown). The Experiences in Close Relationships-Revised
Table 1
Sociodemographic and background characteristics of the sample.
SSA BD DD Total P-value
n % n % n % n %
Number 113 28.2 99 24.8 188 47.0 400 100.0
Female 54 47.8 63 63.6 146 77.7 263 65.7 < 0.001a
Marital status < 0.001b
Married 2 1.8 20 20.2 39 21.0 61 15.4
Cohabitation 8 7.3 17 17.2 29 15.6 54 13.7
Divorced 16 14.5 29 29.3 36 19.4 81 20.5
Widowed 3 2.7 1 1.0 3 1.6 7 1.8
Unmarried 81 73.6 32 32.3 79 42.5 192 48.6
Childless
patients




68 61.8 71 71.7 121 65.1 260 65.8 0.307a
Smokers 57 51.8 50 50.5 78 42.2 185 47.0 0.197a
Inpatients 36 31.9 20 20.2 34 18.1 90 22.5 0.028a
Mean (SD) Mean (SD) Mean (SD) Mean (SD) P-value
Age 44.3 (12.4) 43.4 (12.3) 41.2 (13.3) 42.6 (12.9) 0.112b
Age of onset 30.4 (13.1) 34.7 (14.2) 35.2 (14.3) 33.0 (14.2) 0.009b
Duration
of illness
14.6 (13.8) 9.1 (8.6) 6.3 (4.8) 9.8 (8.7) 0.001b












Mean* (SD) 9.4 (5.5) 10.8 (4.4) 11.0 (4.8)
Percentiles
10 4.0 4.0 4.0
25 5.0 7.0 8.0
50 10.0 12.0 12.0
75 14.0 14.0 15.0
90 16.0 16.0 17.0
SSA: schizophrenia or schizoaffective disorder; BD: bipolar disorder; DD:
depressive disorder.
* P = 0.040 (Kruskal–Wallis test).
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adult attachment style on anxiety and avoidance subscales. The
General Self-Efficacy scale (GSE) [46] is a self-report 10-item
instrument to assess perceived self-efficacy regarding stressful life
events. The McLean Screening Instrument for Borderline Person-
ality Disorder (MSI-BPD, hereafter MSI) [47] is a self-report 10-
item questionnaire to detect the possibility of borderline
personality disorder (BPD). The Trauma and Distress Scale (TADS)
[48,49] is a self-report 43-item scale for the assessment of early
(childhood and early adulthood) traumatic experiences and
distress. All of the scales had at least good internal consistency
(Chronbach’s alpha for BDI – 0.91; for S5N – 0.85; for ECR anxiety
scale – 0.95 and avoidance scale – 0.97; for GSE – 0.93; for MSI –
0.92; and for TADS – 0.80).
2.5. Statistical analyses
The differences between nominal sociodemographic variables
across diagnostic groups were explored with Chi-square test, and
between continuous variables with the Kruskal–Wallis test.
Nominal dichotomous variables, such as sex, presence or absence
of children, education (primary or secondary and higher), smoking
status, and care unit (in- or outpatients) were compared with mean
OASIS scores using t-tests or Mann–Whitney U-tests; for marital
status the Kruskal–Wallis test was used. The relationships between
the OASIS and continuous variables (age, age of onset of illness, and
duration of illness) were tested with bivariate correlation analysis.
Age of onset and duration of illness were determined based on time
of occurrence of the first symptoms reported by the patients. For
investigation of the clinical hypothesis of the study, the differences
between both the mean total scores and separate item scores of
OASIS across the diagnostic groups the Kruskal–Wallis test was
used. Bivariate correlation analysis (BCA; Spearman’s coefficient)
was used to estimate correlation of OASIS with BDI, S5N, MSI, GSE,
TADS, and ECR anxiety and avoidance; analysis was performed for
each group of patients separately. In order to test the theoretical
hypothesis of the study, linear regression model was built to
estimate the association between the OASIS (dependent variable)
and measures correlated with it in BCA (independent variables)
across all diagnostic groups. These measures were all of the above-
mentioned variables, with the exception of ECR avoidance. In
addition, sex and age were included in the analysis. Separate
regression models were constructed for each diagnostic group. As
additional analysis and partly to avoid the problem of multi-
collinearity, regression analysis was performed for all independent
variables and then with BDI and S5N excluded one at a time and
simultaneously. Statistical significance was set at P < 0.05.
Statistical analysis was performed using the Statistical Package
for the Social Sciences [50].
3. Results
3.1. Sociodemographic and background data
Table 1 shows the main sociodemographic characteristics of the
sample. The patients were middle-aged and there was no
significant difference in mean age between diagnostic groups
(P = 0.112). The sex distribution differed markedly, with a
preponderance of females in the DD and BD groups, but nearly
equal distribution in the SSA group (P < 0.001). SSA patients had a
family and children less often than BD and DD patients (P < 0.001).
The proportion of childless patients in the DD group was higher
than in the BD group. No significant differences in educational level
or proportion of smokers were found. Of all the diagnostic groups,
the SSA group had a highest proportion of inpatients.3.2. Overall Anxiety Severity and Impairment Scale (OASIS)
The mean scores of OASIS (Table 2) from 9.4 to 11.0 were
seemingly close to each other, but nevertheless differed signifi-
cantly (P = 0.040). Of specific subgroups, childless SSA and DD
patients had higher OASIS scores (P = 0.001 and P = 0.026,
respectively), as did smokers with BD (P = 0.006). Analyses
demonstrated no significant relations between OASIS scores and
other sociodemographic and background variables (data not
shown). Overall, from 40.2% to 55.6% of the patients of all groups
reported experiencing anxiety frequently or constantly; from
41.2% to 43.8% felt anxiety as severe or extreme (Table 3). SSA
patients felt frequent or constant anxiety less often than BD and DD
patients (P = 0.010) and did not avoid anxiety-provoking situations
as often as BD and DD patients (P = 0.009). Severe or extreme
anxiety interfered with functioning at home, school, and work in
33.9% of SSA, 40.4% of BD, and 40.1% of DD patients (OASIS item 4).
The corresponding figures for anxiety-induced impairment in
social life and relationships were 35.7%, 33.4%, and 44.3% (OASIS
item 5). However, the differences between diagnostic groups in
these two last items were not statistically significant.
Table 3
Results of the OASIS questionnaire items by diagnostic group.
SSA (n = 113) BD (n = 99) DD (n = 188)
n % n % n %
How often have you felt anxious*
No anxiety 18 16.1 4 4.0 10 5.3
Infrequent anxiety 21 18.8 15 15.2 29 15.5
Occasional anxiety 28 25.0 29 29.3 44 23.5
Frequent anxiety 32 28.6 41 41.4 76 40.6
Constant anxiety 13 11.6 10 10.1 28 15.0
When you have felt anxious, how intense or severe was your anxiety
Little or None 16 14.3 3 3.0 7 3.7
Mild 18 16.1 20 20.2 35 18.7
Moderate 29 25.9 35 35.4 68 36.4
Severe 42 37.5 31 31.3 68 36.4
Extreme 7 6.3 10 10.1 9 4.8
How often did you avoid situations, places, objects, or activities because of
anxiety or fear**
None 23 20.4 14 14.1 20 10.6
Infrequent 23 20.4 14 14.1 34 18.1
Occasional 38 33.6 29 29.3 54 28.7
Frequent 20 17.7 32 32.3 65 34.6
All the time 9 8.0 10 10.1 15 8.0
How much did your anxiety interfere with your ability to do the things you
needed to do at work, at school, or at home
None 27 24.1 11 11.1 18 9.6
Mild 17 15.2 21 21.2 36 19.3
Moderate 30 26.8 27 27.3 58 31.0
Severe 26 23.2 32 32.3 52 27.8
Extreme 12 10.7 8 8.1 23 12.3
How much has anxiety interfered with your social life and relationships
None 22 19.6 8 8.1 16 8.6
Mild 22 19.6 24 24.2 46 24.6
Moderate 28 25.0 34 34.3 44 23.5
Severe 29 25.9 26 26.3 51 27.3
Extreme 11 9.8 7 7.1 30 16.0
SSA: schizophrenia or schizoaffective disorder; BD: bipolar disorder; DD:
depressive disorder.
* P = 0.010.
** P = 0.009 (Kruskal–Wallis test).
Table 5
Clinical correlates for OASIS by diagnosis group (linear regression analysis). The
main analysis showed in the first model (analysis with all variables).
SSA (n = 113) BD (n = 99) DD (n = 188)
B Sig. B Sig. B Sig.
Analysis with all variables
Sex –.845 .396 –.647 .370 –.595 .415
Age –.005 .900 .037 .219 .036 .127
BDI .081 .213 .198 .000 .180 .000
S5N .148 .007 .086 .053 .094 .007
MSI .388 .084 .008 .966 .214 .152
GSE –.007 .934 .072 .330 .007 .913
TADS .011 .674 .029 .094 .021 .110
ECR anxiety .024 .214 .002 .879 –.014 .271
Analysis with BDI excluded
Sex –.815 .415 –.749 .368 –.499 .540
Age .001 .981 .053 .126 .037 .159
S5N .184 .000 .145 .004 .144 .000
MSI .410 .069 .124 .565 .257 .122
GSE –.017 .836 .002 .979 –.106 .123
TADS .019 .456 .050 .011 .043 .003
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Overall, OASIS correlated mainly with the same scales in all
groups (Table 4). The strong correlation between anxiety and
depression symptoms was found in each diagnostic group.
Noteworthy is that all patients experienced fairly severe depres-
sive symptoms (data not shown). High neuroticism and anxiety
correlated strongly in the SSA group and moderately in the BD and
DD groups. In all patients, anxiety symptoms had a moderate direct
correlation with the symptoms of borderline personality disorderTable 4
Bivariate correlation between OASIS and other rating scales by diagnostic group
(Spearman’s rank).




SSA (n = 113) .700*** .712*** .588*** –.448*** .498*** .350** –.017
BD (n = 99) .729*** .569*** .447*** –.398*** .498*** .365*** .232*
DD (n = 188 .700*** .584*** .457*** –.440*** .413*** .273** .203*
SSA: schizophrenia or schizoaffective disorder; BD: bipolar disorder; DD:
depressive disorder; OASIS: Overall Anxiety Severity and Impairment Scale; BDI:
Beck Depression Inventory; S5N: ‘‘Short Five’’ Neuroticism Scale; MSI: McLean
Screening Instrument for Borderline Personality Disorder; GSE: General Self-
Efficacy scale; TADS: Trauma and Distress Scale; ECR: Experiences in Close
Relationships; ECR anxiety: ECR questionnaire items 1–18; ECR avoidance: ECR
questionnaire items 19–36.
* P  0.05.
** P  0.01.
*** P  0.001.(MSI) and early trauma (TADS), and a weak direct correlation with
anxious attachment style (ECR anxiety). Across all the diagnostic
groups, patients with more severe anxiety symptoms tended to
have a lower self-efficacy level, as there was a moderate inverse
correlation between OASIS and GSE. In addition, avoidant
attachment style (ECR avoidance) showed a weak direct correla-
tion with anxiety symptoms only in the BD and DD groups.
3.4. Regression analysis
Of all the variables, symptoms of depression (BDI) and high
neuroticism (S5N) were the most strongly associated with OASIS in
different regression models (Table 5). Surprisingly, in the main
model with all the variables, neuroticism showed a significant
weight in the SSA and DD groups, but not in the BD group. In the
same model, depressive symptoms were significantly associated
with OASIS in the BD and DD groups. When BDI and S5N were both
excluded from the regression model, the symptoms of borderline
personality disorder and level of self-efficacy acquired a regression
weight in each diagnostic group and the early trauma and distress
in the BD and DD groups.
4. Discussion
The current study investigated comorbid anxiety symptoms
from both clinical and theoretical viewpoints. The clinical aim was
to examine the point prevalence and level of comorbid anxiety
symptoms across the major psychiatric disorders in specializedECR anxiety .025 .208 .000 .981 –.020 .170
Analysis with S5N excluded
Sex –1.008 .338 –.888 .222 –.368 .620
Age –.014 .741 .022 .450 .038 .117
BDI .181 .002 .218 .000 .204 .000
MSI .585 .011 .169 .331 .382 .007
GSE –.090 .257 –.001 .982 –.061 .320
TADS .050 .998 .023 .181 .018 .177
ECR anxiety .031 .129 .012 .450 –.007 .564
Analysis with BDI and S5N excluded
Sex –1.042 .356 –1.202 .163 –.104 .903
Age –.002 .969 .029 .402 .041 .145
MSI .812 .001 .436 .030 .544 .001
GSE –.189 .018 –.144 .045 –.242 .000
TADS .017 .554 .043 .035 .043 .005
ECR anxiety .038 .084 .016 .390 –.010 .511
SSA: schizophrenia or schizoaffective disorder; BD: bipolar disorder; DD:
depressive disorder; BDI: Beck Depression Inventory; S5N: ‘‘Short Five’’ Neuroti-
cism Scale; MSI: McLean Screening Instrument for Borderline Personality Disorder;
GSE: General Self-Efficacy scale; ECR anxiety: Experiences in Close Relationships
questionnaire items 1–18; TADS: Trauma and Distress Scale.
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diagnostic groups experienced frequently or constantly severe
or extreme anxiety. However, anxiety was somewhat less frequent
in schizophrenia spectrum disorders (SSA) patients than in their
mood disorders counterparts. The theoretical aim was to explore
the relationship of anxiety with likely covariates and putative risk
factors, and determine whether these are similar across the
disorders investigated, which indeed they mostly were.
Strengths of the study include investigation of the similarities
and differences in comorbid anxiety symptoms using the same
methodology in a relatively large sample (total n 400) of
psychiatric patients with different principal diagnoses from the
Helsinki metropolitan area psychiatric services. This enabled
investigating the covariates and putative risk factors of anxiety
symptoms across the major diagnostic groups simultaneously.
Anxiety symptoms were measured using the Overall Anxiety
Severity and Impairment Scale (OASIS), which have been found to
be a valid and reliable brief scale [42]. In addition to frequency and
intensity of anxiety symptoms and avoidance due to these
symptoms, the OASIS also captures anxiety-related functional
and behavioral impairment [51].
Our study had several limitations. First, it was a cross-sectional
study, thus not enabling causal inferences regarding risk factors for
anxiety symptoms, or any analyses of temporal variations. Second,
we used only a self-report measure of anxiety symptoms and did
not have interview-based measures of anxiety symptoms. Third,
the response rate was only 33%, probably due to sampling
conducted during busy routine clinical practice and the length
of the survey. However, according to the analysis of representa-
tiveness, our sample did not differ from the total patient
population regarding age or gender. In terms of other demographic
characteristics, our sample corresponded to the large screening-
based Vantaa Depression Study and Jorvi Bipolar Study
[18,52]. Fourth, the presence, intensity, and quality of current
psychotic symptoms were not measured, and thus, their role in
comorbidity of anxiety remains unclear. Fifth, retrospective bias
may exist in relation to some measurement scales, as patients may
not always recollect past events and symptoms. Sixth, the principal
clinical diagnoses were not based on structured interviews,
although they were validated by the authors based on patients’
psychiatric records. Seventh, the study includes multiple statistical
analyses, so problems of multiple testing need to be considered.
However, there were two hypotheses and one statistical test for
each. The remaining analyses are either presented for descriptive
purposes, or to confirm coherence and robustness of the
hypothesis-related findings irrespective of methodological details.
The clinical aim of the study was to investigate prevalence and
patterns of comorbid anxiety symptoms across the disorders. The
mean OASIS total scores in all three subgroups clearly exceeded the
cut-off score of eight points, usually indicating presence of an AD
[42]. Nearly half of our patients in all groups frequently or
constantly experienced severe or extreme anxiety. The proportions
of our patients with frequent and severe anxiety were similar to
findings of lifetime comorbid AD in the same diagnostic groups in
earlier reports [6–8]. However, direct comparison of our results
with those of previous studies is difficult due to methodological
differences and since the published reports rely mostly on
categorically diagnosed AD rather than on anxiety symptoms. Of
all three subgroups, the SSA patients reported frequent anxiety and
anxiety-related avoidance behavior less often than their mood
disorder counterparts. The lower rate of comorbid anxiety
symptoms in the SSA group could be explained in several ways.
First, more frequent anxiety symptoms in patients with mood
disorders could be expected because of strong co-incidence of
internalizing disorders [21,24–26] as well as temporal covariation
of depressive and anxiety symptoms among them [22,53]. However,virtually all of the patients, irrespective of their principal diagnosis,
suffered from clinically significant depressive symptoms, which
strongly correlated with anxiety symptoms, albeit more in patients
with mood disorders than in those with SSA. Second, the majority of
SSA patients were outpatients, and thus, in relatively stable
condition. For this reason, they probably less often had florid
positive symptoms or primary disorder-induced anxiety symptoms
to report [9]. Third, avoidance behavior may be less prominent in
SSA patients due to their common withdrawal from social roles, and
hence, less frequent exposure to common anxiety-provoking
situations [54–56]. Furthermore, these patients often experience
negative symptoms, rendering some of them emotionally numb and
indifferent to situations that tend to cause anxiety in other
populations [57]. Nevertheless, despite the observed subgroup
differences, we found comorbid anxiety symptoms to be ubiquitous
among psychiatric patients with major mood or schizophrenia
spectrum disorders, and in almost half of them, reportedly severe.
These findings highlight the importance of the recognition and
treatment of comorbid anxiety symptoms.
The theoretical focus of our study was in investigating the
clinical correlates of comorbid anxiety symptoms and their
potential similarities across major psychiatric disorders. We found
numerous quite similar associations; in addition to the strongest
correlation of the OASIS score with symptoms of depression (BDI)
and neuroticism (S5) in all patients, associations emerged also for
low self-efficacy (GSE) and symptoms of borderline personality
(MSI) across all diagnostic groups, and for early trauma and
distress (TADS) in BD and DD patients. In multivariate regression
analyses of all clinical variables, neuroticism in SSA patients was
associated with comorbid anxiety symptoms as strongly as in DD
patients. Therefore, the personality trait of neuroticism seems to be
an underlying factor for comorbid anxiety beyond the internalizing
domain, thus possibly also within schizophrenia spectrum
disorders.
Presence of depressive symptoms and high neuroticism, thus,
persisted as independent covariates for anxiety symptoms in
multivariate regression models. There were also other correlates
associated with anxiety, but not consistently after controlling for
the above two factors. These other correlates were mostly the same
across the diagnostic groups, with only TADS not being associated
with OASIS in the SSA group. Numerous studies suggest an
association between experienced childhood trauma and psychotic
and mood disorders [31,37,58]. Early traumatic experiences may
be connected to a higher level of neuroticism as well [59,60]. Hence,
trauma could potentially contribute to comorbid anxiety as a distal
cause as well as a neuroticism-mediated condition. In addition, in
our patients self-reported symptoms of borderline personality
disorder were associated with anxiety symptoms in all diagnostic
groups. This finding is consistent with other studies showing that
up to 90% of patients with borderline personality disorder
experience comorbid anxiety [34,61]. Probably unsurprisingly,
also self-efficacy was inversely associated with the level of anxiety
and regardless of the primary diagnoses. Poor self-efficacy appears
to be a significant factor in development, severity, and treatment of
anxiety disorders [32,62]. Our finding suggests that the same logic
applies to comorbid anxiety as a continuum. In short, the broad
similarity of correlates across all diagnostic groups supports the
view that comorbid anxiety symptoms have numerous common
background factors, and thus, could be due to a non-aligned
condition rather than a direct consequence of the primary
psychiatric pathology. While these associations are interesting,
it is important to bear in mind their inconsistent significance in
multivariate analyses. Analyses of mediation or moderation were
beyond the scope of this study. Overall, the most robust and
consistent associations with symptoms of anxiety in all subgroups
were those with current depressive symptoms and neuroticism.
B. Karpov et al. / European Psychiatry 37 (2016) 1–765. Conclusion
Comorbid anxiety symptoms are highly prevalent among
psychiatric patients with major mood or schizophrenia spectrum
disorders, and in almost half of them, reportedly severe. The
prevalence of symptoms is somewhat higher in the former group
than in the latter. In addition, anxiety-related avoidance behavior
is less frequent in patients with schizophrenia spectrum disorders.
Anxiety symptoms appear strongly related to both concurrent
presence of depressive symptoms and personality characteristics,
particularly high neuroticism, regardless of the principal diagnosis.
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